Most patients feel satisfied with smaller portions without conscious dieting, making adherence easier and weight loss more sustainable than traditional calorie counting
However, many patients with metabolic syndrome benefit from GLP-1 therapy because it addresses multiple risk factors simultaneously
continued 5.5% additional loss in tirzepatide continuation group SURMOUNT-4: Weight maintenance trial confirming sustained benefits over extended treatment [1] November 2023: FDA Approval for Obesity Zepbound (tirzepatide) approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities
At this performance-focused tier, doses of 5-10 mg before training sessions, three to five times per week, represent the upper range of current clinical practice [2]
Visceral fat baseline, IGF-1, fasting glucose, and lipid panel anchor the decision
Before taking this medicine, inform your doctor about all the other medicines you are taking to avoid interactions
